Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

June 17, 2024

https://www.globenewswire.com/news-release/2024/06/17/2899667/0/en/Mustang-Bio-Announces-Favorable-Efficacy-and-Safety-Data-from-Complete-Waldenstrom-Macroglobulinemia-Cohort-of-Phase-1-2-Clinical-Trial-of-MB-106-CD20-Targeted-Autologous-CAR-T-The.html

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months

All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.